At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of the breast with metastatic disease
- ✓HER2 expression status must be determined by ECOG Pathology Coordinating Office; will be used at registration
- ✓ECOG performance status 0, 1, or 2
- ✓Normal left ventricular ejection fraction at or above institutional lower limits of normal
- ✕Prior chemotherapy for advanced/metastatic disease
- ✕Prior adjuvant anthracycline or any anthracycline-containing regimen, or any anthracenedione-containing regimen
- ✕Prior therapy with Herceptin (trastuzumab)
- ✕Extensive prior radiotherapy (>25% marrow-containing bone or prior photon internal mammary node treatment)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of Doxil and Taxotere ± Herceptin in Advanced Breast Cancer
In Brief
A Phase 2 clinical trial evaluating pegylated liposomal doxorubicin hydrochloride, docetaxel, and 2 other interventions for Recurrent Breast Cancer and Stage IV Breast Cancer. Completed, enrolled 84 participants across 1 site.
Detailed Summary
Phase II trial to study the effectiveness of combination chemotherapy with or without trastuzumab in treating women who have metastatic breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Correlative studies